Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619

Shinya Watanabe; Teruyo Ito; Keiichi Hiramatsu
December 2007
Journal of Antimicrobial Chemotherapy (JAC);Dec2007, Vol. 60 Issue 6, p1384
Academic Journal
Objectives The aim of the study was to test in vitro activities of the novel des-F(6)-quinolone DX-619 against methicillin-resistant staphylococci (MRS) isolated in hospitals and communities and to compare its activity with other quinolones, sitafloxacin and levofloxacin, and antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus infection, including vancomycin, teicoplanin, arbekacin, linezolid and quinupristin/dalfopristin. Methods MICs were determined by the agar dilution method using healthcare-associated MRS (S. aureus including strains with reduced susceptibility to vancomycin, 103; coagulase-negative staphylococci, 87) and community-associated MRS (S. aureus including non-multiresistant oxacillin-resistant strains, 37; coagulase-negative staphylococci, 92). The quinolone resistance-determining regions of gyrA, gyrB, grlA and grlB genes from six strains with reduced susceptibility to DX-619 were sequenced. Results DX-619 showed the lowest MIC90 values for all categories of strains tested, irrespective of the degree of glycopeptide resistance. The six strains with MIC values of >128 mg/L of levofloxacin commonly carried two mutations in gyrA and two mutations in grlA. DX-619 showed potent activity against strains with MIC values of 2 mg/L. Conclusions DX-619 was potent against all MRS tested, suggesting that it would be a promising candidate for the treatment of methicillin-resistant S. aureus infection if sufficient in vivo concentrations were safely attained.


Related Articles

  • In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. Cong-Ran Li; Yi Li; Guo-Qing Li; Xin-Yi Yang; Wei-Xin Zhang; Ren-Hui Lou; Jing-Fang Liu; Min Yuan; Shan Cen; Li-Yan Yu; Li-Xun Zhao; Jian-Dong Jiang; Xue-Fu You; Philip Huang // Journal of Antimicrobial Chemotherapy (JAC);Nov2010, Vol. 65 Issue 11, p2411 

    Objectives To evaluate the in vivo antibacterial efficacy of nemonoxacin, a novel C8-methoxy non-fluorinated quinolone in murine systemic and local infection models. Methods The efficacy of nemonoxacin in systemic infections was evaluated in mouse peritonitis models using isolates of...

  • Hospital and Community Fluoroquinolone Use and Resistance in Staphylococcus aureus and Escherichia coli in 17 US Hospitals. MacDougall, Conan; Powell, J. Patrick; Johnson, Christopher K.; Edmond, Michael B.; Polk, Ronald E. // Clinical Infectious Diseases;8/15/2005, Vol. 41 Issue 4, p435 

    Background. Fluoroquinolones are widely prescribed in hospitals and the community. Previous studies have shown associations between fluoroquinolone use and isolation of fluoroquinolone-resistant Eshcerichia coli and methicillin-resistant Staphylococcus aureus (MRSA). We performed an...

  • A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model. Hiroshi Sasaki; Masamichi Fukuda // Japanese Journal of Ophthalmology;May2008, Vol. 52 Issue 3, p211 

    Abstract Purpose  Moxifloxacin, a fourth-generation fluoroquinolone (FQ), was compared to levofloxacin, a thirdgeneration FQ, for preventing FQ-resistant, methicillin-resistant Staphylococcus aureus (FQrMRSA) endophthalmitis in a rabbit model. Methods  Three regimens of topical...

  • Hardy bacteria looms large in 21st century. Kohl, Martin // Dermatology Times;Oct99, Vol. 20 Issue 10, p1 

    Reports on the emergence of a methicillin-resistant staphylococcus bacteria. Overuse of antibiotics as reason behind the emergence of antibiotic resistant bacteria; Evidence showing that use of antibiotics in treating dermatologic problems may lead to antibiotic resistant bacteria.

  • ANTIMICROBIAL AGENT RESISTANCE. Peterson, Lance R. // Managed Healthcare Executive;Jun2002 Supplement 1, Vol. 12 Issue 6, p20 

    Analyzes the potential impact of emerging resistance to fluoroquinolones, a quinolones antibacterial agent. Properties of fluoroquinolones; Efficacy for treatment of infections; Strategies to prevent the continued development of resistance to fluoroquinolones.

  • A New Approach for the Discovery of Antibiotics by Targeting Non-Multiplying Bacteria: A Novel Topical Antibiotic for Staphylococcal Infections. Yanmin Hu; Shamaei-Tousi, Alireza; Yingjun Liu; Coates, Anthony // PLoS ONE;2010, Vol. 5 Issue 7, p1 

    In a clinical infection, multiplying and non-multiplying bacteria co-exist. Antibiotics kill multiplying bacteria, but they are very inefficient at killing non-multipliers which leads to slow or partial death of the total target population of microbes in an infected tissue. This prolongs the...

  • Breast Abscess and Community-Acquired Resistant Staphylococcus aureus: Case Report and Literature Review. Ventolini, Gary; Barhan, Sheela; Haas, Jennifer // Journal of Gynecologic Surgery;Oct2013, Vol. 29 Issue 5, p251 

    Background: Mastitis is a complication that develops in 1%-24% of breastfeeding women. Breast abscesses complicate mastitis in 5%-11% of cases in the first 12 weeks after birth with Staphylococcus aureus being the most common microorganism retrieved from from breast abscesses. A small number of...

  • Infection control in the community - do we have a problem? Wrobel, Bernadine; Maryon, Beth // Journal of Community Nursing;Jun2006, Vol. 20 Issue 6, p16 

    Provides information on a study which investigated the incidence of methicillin resistant staphylococcus aureus (MRSA) infection in a suburb of London, England. Factors considered in the assessment process; Main routes of infection; Factors contributing to MRSA incidence.

  • Characterization of oxacillin-susceptible mecA -positive Staphylococcus aureus : a new type of MRSA. Yasuko Hososaka; Hideaki Hanaki; Harumi Endo; Yumiko Suzuki; Zenzo Nagasawa; Yoshihito Otsuka; Taiji Nakae // Journal of Infection & Chemotherapy (Springer Science & Business;Apr2007, Vol. 13 Issue 2, p79 

    Abstract  Methicillin-resistant Staphylococcus aureus (MRSA) has been defined as S. aureus having the mecA gene or showing a minimum inhibitory concentration (MIC) of oxacillin higher than 4 mg/l. However, some clinical isolates are mecA-positive and oxacillin-susceptible....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics